Gleaning insights from fecal microbiota transplantation and probiotic studies for the rational design of combination microbial therapies

Clinical Microbiology Reviews

Volumn 30, Issue 1, 2017, Pages 191-231

  Hudson, Lauren E ^a   Anderson, Sarah E ^a   Corbett, Anita H ^b   Lamb, Tracey J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Clostridium difficile; Fecal microbiota transplantation; Microbiota; Probiotics; Ulcerative colitis

Indexed keywords

AMINOPENICILLIN; BACTERIAL TOXIN; BETA CATENIN; CEPHALOSPORIN; CHEMOKINE RECEPTOR CCR2; CLINDAMYCIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FORDIN; GAMMA INTERFERON; GLIADIN; GRANULOCYTE CHEMOTACTIC PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN; MUCIN 1; MUCIN 2; OCCLUDIN; PEPTIDES AND PROTEINS; PROBIOTIC AGENT; PROTEIN P130; PROTON PUMP INHIBITOR; SECONDARY LYMPHOID TISSUE CHEMOKINE; SYMPLEKIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VANCOMYCIN;

CLINICAL TRIAL (TOPIC); CLOSTRIDIUM DIFFICILE INFECTION; DEPOLYMERIZATION; DISEASE PREDISPOSITION; FECAL MICROBIOTA TRANSPLANTATION; HOSPITALIZATION; HUMAN; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASE; INTESTINE MUCOSA PERMEABILITY; LACTOBACILLUS; MICROBIAL COLONIZATION; MICROBIAL DIVERSITY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK FACTOR; SACCHAROMYCES BOULARDII; ULCERATIVE COLITIS; ADULT; COLITIS, ULCERATIVE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; INFLAMMATORY BOWEL DISEASES; ISOLATION AND PURIFICATION; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; TREATMENT OUTCOME;

ADULT; CLINICAL TRIALS AS TOPIC; CLOSTRIDIUM DIFFICILE; COLITIS, ULCERATIVE; COMBINED MODALITY THERAPY; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECAL MICROBIOTA TRANSPLANTATION; HUMANS; INFLAMMATORY BOWEL DISEASES; PROBIOTICS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 85007188919     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00049-16     Document Type: Review

References (386)

1. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, Kelly C, Khoruts A, Louie T, Martinelli LP, Moore TA, Russell G, Surawicz C. 2011. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 9: 1044-1049. https:// doi.org/10.1016/j.cgh.2011.08.014.
2. Choi HH, Cho Y. 2016. Fecal microbiota transplantation: current applications, effectiveness, and future perspectives. Clin Endosc 49: 257-265. https://doi.org/10.5946/ce.2015.117.
3. Hamilton MJ, Weingarden AR, Unno T, Khoruts A, Sadowsky MJ. 2013. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 4: 125-135. https://doi.org/10.4161/gmic.23571.
4. Kazerouni A, Burgess J, Burns LJ, Wein LM. 2015. Optimal screening and donor management in a public stool bank. Microbiome 3: 75. https:// doi.org/10.1186/s40168-015-0140-3.
5. Drekonja D, Reich J, Gezahegn S, Greer N, Shaukat A, MacDonald R, Rutks I, Wilt TJ. 2015. Fecal microbiota transplantation for Clostridium difficile infection: a systematic review. Ann Intern Med 162: 630-638. https://doi.org/10.7326/M14-2693.
6. Schwartz M, Gluck M, Koon S. 2013. Norovirus gastroenteritis after fecal microbiota transplantation for treatment of Clostridium difficile infection despite asymptomatic donors and lack of sick contacts. Am J Gastroenterol 108: 1367. https://doi.org/10.1038/ajg.2013.164.
7. Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, Aronia-dis O, Barto A, Borody T, Giovanelli A, Gordon S, Gluck M, Hohmann EL, Kao D, Kao JY, McQuillen DP, Mellow M, Rank KM, Rao K, Ray A, Schwartz MA, Singh N, Stollman N, Suskind DL, Vindigni SM, Youngster I, Brandt L. 2014. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 109: 1065-1071. https://doi.org/10.1038/ajg.2014.133.
8. Di Bella S, Gouliouris T, Petrosillo N. 2015. Fecal microbiota transplantation (FMT) for Clostridium difficile infection: focus on immunocompromised patients. J Infect Chemother 21: 230-237. https://doi.org/10.1016/j.jiac.2015.01.011.
9. De Leon LM, Watson JB, Kelly CR. 2013. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 11: 1036-1038. https:// doi.org/10.1016/j.cgh.2013.04.045.
10. Brandt LJ, Aroniadis OC, Mellow M, Kanatzar A, Kelly C, Park T, Stollman N, Rohlke F, Surawicz C. 2012. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 107: 1079-1087. https://doi.org/10.1038/ ajg.2012.60.
11. Alang N, Kelly CR. 2015. Weight gain after fecal microbiota transplantation. Open Forum Infect Dis 2: ofv004. https://doi.org/10.1093/ofid/ ofv004.
12. Paramsothy S, Borody TJ, Lin E, Finlayson S, Walsh AJ, Samuel D, Van den Bogaerde J, Leong RWL, Connor S, Ng W, Mitchell HM, Kaakoush N, Kamm MA. 2015. Donor recruitment for fecal microbiota transplantation. Inflamm Bowel Dis 21: 1600-1606. https://doi.org/10.1097/ MIB.0000000000000405.
13. Amirtha T. 2016. Banking on stool despite an uncertain future. Science 352: 1261-1262. https://doi.org/10.1126/science.352.6291.1261.
14. Vyas D, Aekka A, Vyas A. 2015. Fecal transplant policy and legislation. World J Gastroenterol 21: 6-11. https://doi.org/10.3748/wjg.v21.i1.6.
15. McFarland L. 2006. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 101: 812-822. https://doi.org/10.1111/ j.1572-0241.2006.00465.x.
16. Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW. 2014. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol 7: 473-487. https://doi.org/10.2147/CEG.S27530.
17. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm M, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J. 2004. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53: 1617-1623. https://doi.org/10.1136/gut.2003.037747.
18. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. 2009. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 104: 437-443. https://doi.org/10.1038/ajg.2008.118.
19. Claesson MJ, van Sinderen D, O’Toole PW. 2008. Lactobacillus phylogenomics-towards a reclassification of the genus. Int J Syst Evol Microbiol 58: 2945-2954. https://doi.org/10.1099/ijs.0.65848-0.
20. MacKenzie D, Defernez M, Dunn W, Brown M, Fuller L, de Herrera S, Günther A, James S, Eagles J, Philo M, Goodacre R, Roberts I. 2008. Relatedness of medically important strains of Saccharomyces cerevisiae as revealed by phylogenetics and metabolomics. Yeast 25: 501-512. https://doi.org/10.1002/yea.1601.
21. Brandt K, Barrangou R. 2016. Phylogenetic analysis of the Bifidobacterium genus using glycolysis enzyme sequences. Front Microbiol 7: 657. https://doi.org/10.3389/fmicb.2016.00657.
22. Danese S, Fiocchi C. 2011. Ulcerative colitis. N Engl J Med 365: 1713-1725. https://doi.org/10.1056/NEJMra1102942.
23. Rupnik M, Wilcox MH, Gerding DN. 2009. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 7: 526-536. https://doi.org/10.1038/nrmicro2164.
24. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinisch W, Lee CH. 2015. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149: 102-109. https://doi.org/10.1053/j.gastro.2015.04.001.
25. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen J, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. 2015. Burden of Clostridium difficile infection in the United States. N Engl J Med 372: 825-834. https://doi.org/10.1056/NEJMoa1408913.
26. McFarland L, Mulligan M, Kwok R, Stamm W. 1989. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320: 204-210. https://doi.org/10.1056/NEJM198901263200402.
27. Kim KH, Fekety R, Batts DH, Brown D, Cudmore M, Silva J, Waters D. 1981. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis 143: 42-50. https://doi.org/10.1093/infdis/143.1.42.
28. Lawley TD, Clare S, Deakin LJ, Goulding D, Yen JL, Raisen C, Brandt C, Lovell J, Cooke F, Clark TG, Dougan G. 2010. Use of purified Clostridium difficile spores to facilitate evaluation of health care disinfection regimens. Appl Environ Microbiol 76: 6895-6900. https://doi.org/10.1128/ AEM.00718-10.
29. Sorg JA, Sonenshein AL. 2008. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol 190: 2505-2512. https://doi.org/10.1128/JB.01765-07.
30. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31: 431-455. https:// doi.org/10.1086/651706.
31. Curry SR, Muto CA, Schlackman JL, Pasculle AW, Shutt KA, Marsh JW, Harrison LH. 2013. Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission. Clin Infect Dis 57: 1094-1102. https://doi.org/10.1093/cid/cit475.
32. Kyne L, Warny M, Qamar A, Kelly CP. 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342: 390-397. https://doi.org/10.1056/NEJM200002103420604.
33. Carter GP, Rood JI, Lyras D. 2012. The role of toxin A and toxin B in the virulence of Clostridium difficile. Trends Microbiol 20: 21-29. https:// doi.org/10.1016/j.tim.2011.11.003.
34. Borriello SP, Wren BW, Hyde S, Seddon S, Sibbons P, Krishna MM, Tabaqchali S, Manek S, Price AB. 1992. Molecular, immunological, and biological characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun 60: 4192-4199.
35. Kuehne SA, Collery MM, Kelly ML, Cartman ST, Cockayne A, Minton NP. 2014. Importance of toxin A, toxin B, and CDT in virulence of an epidemic Clostridium difficile strain. J Infect Dis 209: 83-86. https:// doi.org/10.1093/infdis/jit426.
36. Drudy D, Fanning S, Kyne L. 2007. Toxin A-negative, toxin B-positive Clostridium difficile. Int J Infect Dis 11: 5-10. https://doi.org/10.1016/ j.ijid.2006.04.003.
37. LaFrance ME, Farrow M, Chandrasekaran R, Sheng J, Rubin DH, Lacy DB. 2015. Identification of an epithelial cell receptor responsible for Clostridium difficile TcdB-induced cytotoxicity. Proc Natl Acad Sci U S A 112: 7073-7078. https://doi.org/10.1073/pnas.1500791112.
38. Na X, Kim H, Moyer MP, Pothoulakis C, LaMont JT. 2008. gp96 is a human colonocyte plasma membrane binding protein for Clostridium difficile toxin A. Infect Immun 76: 2862-2871. https://doi.org/10.1128/ IAI.00326-08.
39. Tucker KD, Wilkins TD. 1991. Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X, and Y. Infect Immun 59: 73-78.
40. Yuan P, Zhang H, Cai C, Zhu S, Zhou Y, Yang X, He R, Li C, Guo S, Li S, Huang T, Perez-Cordon G, Feng H, Wei W. 2015. Chondroitin sulfate proteoglycan 4 functions as the cellular receptor for Clostridium difficile toxin B. Cell Res 25: 157-168. https://doi.org/10.1038/cr.2014.169.
41. Just I, Selzer J, Wilm M, von Eichel-Streiber C, Mann M, Aktories K. 1995. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 375: 500-503. https://doi.org/10.1038/375500a0.
42. Just I, Wilm M, Selzer J, Rex G, Von Eichel-Streiber C, Mann M, Aktories K. 1995. The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. J Biol Chem 270: 13932-13936. https://doi.org/10.1074/jbc.270.23.13932.
43. Fiorentini C, Malorni W, Paradisi S, Giuliano M, Mastrantonio P, Donelli G. 1990. Interaction of Clostridium difficile toxin A with cultured cells: cytoskeletal changes and nuclear polarization. Infect Immun 58: 2329-2336.
44. Brito GA, Fujji J, Carneiro-Filho BA, Lima AAM, Obrig T, Guerrant RL. 2002. Mechanism of Clostridium difficile toxin A-induced apoptosis in T84 cells. J Infect Dis 186: 1438-1447. https://doi.org/10.1086/344729.
45. Gerding DN, Johnson S, Rupnik M, Aktories K. 2014. Clostridium difficile binary toxin CDT: mechanism, epidemiology, and potential clinical importance. Gut Microbes 5: 15-27. https://doi.org/10.4161/gmic.26854.
46. Popoff MR, Rubin EJ, Gill DM, Boquet P. 1988. Actin-specific ADPribosyltransferase produced by a Clostridium difficile strain. Infect Immun 56: 2299-2306.
47. Hecht G, Pothoulakis C, LaMont JT, Madara JL. 1988. Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J Clin Invest 82: 1516-1524. https://doi.org/10.1172/JCI113760.
48. Nusrat A, Turner JR, Verkade P, Madara L, Parkos CA. 2001. Clostridium difficile toxins disrupt epithelial barrier function by altering membrane microdomain localization of tight junction proteins. Infect Immun 69: 1329-1336. https://doi.org/10.1128/IAI.69.3.1329-1336.2001.
49. Kasendra M, Barrile R, Leuzzi R, Soriani M. 2014. Clostridium difficile toxins facilitate bacterial colonization by modulating the fence and gate function of colonic epithelium. J Infect Dis 209: 1095-1104. https:// doi.org/10.1093/infdis/jit617.
50. Britton RA, Young VB. 2012. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol 20: 313-319. https://doi.org/10.1016/j.tim.2012.04.001.
51. Seekatz A, Rao A, Santhosh K, Young V. 2016. Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent Clostridium difficile infection. Genome Med 8: 47. https://doi.org/10.1186/s13073-016-0298-8.
52. Khanna S, Montassier E, Schmidt B, Patel R, Knights D, Pardi D, Kashyap P. 2016. Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection. Aliment Pharmacol Ther 44: 715-727. https://doi.org/10.1111/apt.13750.
53. Freeman J, Wilcox MH. 1999. Antibiotics and Clostridium difficile. Microbes Infect 1: 377-384. https://doi.org/10.1016/S1286-4579(99)80054-9.
54. McFarland L. 2008. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol 5: 40-48. https://doi.org/10.1038/ncpgasthep1029.
55. McDonald LC, Killgore GE, Thompson A, Owens RC, Kazakova S, Sambol SP, Johnson S, Gerding DN. 2005. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353: 2433-2441. https:// doi.org/10.1056/NEJMoa051590.
56. Antonopoulos DA, Huse SM, Morrison HG, Schmidt TM, Sogin ML, Young VB. 2009. Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. Infect Immun 77: 2367-2375. https://doi.org/10.1128/IAI.01520-08.
57. Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, Viale A, Ubeda C, Xavier J, Pamer EG. 2012. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun 80: 62-73. https://doi.org/10.1128/IAI.05496-11.
58. Gu S, Chen Y, Zhang X, Lu H, Lv T, Shen P, Lv L, Zheng B, Jiang X, Li L. 2016. Identification of key taxa that favor intestinal colonization of Clostridium difficile in an adult Chinese population. Microbes Infect 18: 30-38. https://doi.org/10.1016/j.micinf.2015.09.008.
59. Zhang L, Dong D, Jiang C, Li Z, Wang X, Peng Y. 2015. Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization. Anaerobe 34: 1-7. https:// doi.org/10.1016/j.anaerobe.2015.03.008.
60. Dethlefsen L, Relman DA. 2011. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 108: 4554-4561. https://doi.org/10.1073/pnas.1000087107.
61. Lewis BB, Buffie CG, Carter RA, Leiner I, Toussaint NC, Miller LC, Gobourne A, Ling L, Pamer EG. 2015. Loss of microbiota-mediated colonization resistance to Clostridium difficile infection with oral vancomycin compared with metronidazole. J Infect Dis 212: 1656-1665. https:// doi.org/10.1093/infdis/jiv256.
62. Hung YP, Lee JC, Lin HJ, Liu HC, Wu YH, Tsai PJ, Ko WC. 2015. Clinical impact of Clostridium difficile colonization. J Microbiol Immunol Infect 48: 241-248. https://doi.org/10.1016/j.jmii.2014.04.011.
63. Lees EA, Miyajima F, Pirmohamed M, Carrol ED. 2016. The role of Clostridium difficile in the paediatric and neonatal gut-a narrative review. Eur J Clin Microbiol Infect Dis 35: 1047-1057. https://doi.org/10.1007/s10096-016-2639-3.
64. Keller JM, Surawicz CM. 2014. Clostridium difficile infection in the elderly. Clin Geriatr Med 30: 79-93. https://doi.org/10.1016/ j.cger.2013.10.008.
65. Loo VG, Bourgault A-M, Poirier L, Lamothe F, Michaud S, Turgeon N, Toye B, Beaudoin A, Frost EH, Gilca R, Brassard P, Dendukuri N, Béliveau C, Oughton M, Brukner I, Dascal A. 2011. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 365: 1693-1703. https://doi.org/10.1056/NEJMoa1012413.
66. McDonald LC, Owings M, Jernigan DB. 2006. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 12: 409-415. https://doi.org/10.3201/eid1203.051064.
67. Hopkins MJ, Macfarlane GT. 2002. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J Med Microbiol 51: 448-454. https://doi.org/10.1099/0022-1317-51-5-448.
68. Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, Tigchelaar EF, Jankipersadsing SA, Cenit MC, Harmsen HJM, Dijkstra G, Franke L, Xavier RJ, Jonkers D, Wijmenga C, Weersma RK, Zhernakova A. 2016. Proton pump inhibitors affect the gut microbiome. Gut 65: 740-748. https://doi.org/10.1136/gutjnl-2015-310376.
69. Bacon AEI, Fekety R. 1994. Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic associated diarrhea. Diagn Microbiol Infect Dis 18: 205-209. https://doi.org/10.1016/0732-8893(94)90021-3.
70. Viscidi R, Laughon BE, Yolken R, Bo-Linn P, Moench T, Ryder RW, Bartlett JG. 1983. Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis 148: 93-100. https://doi.org/10.1093/infdis/148.1.93.
71. Kelly C, Pothoulakis C, Orellana J, LaMont J. 1992. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology 102: 35-40. https://doi.org/10.1016/0016-5085(92)91781-X.
72. Leung DY, Kelly CP, Boguniewicz M, Pothoulakis C, LaMont JT, Flores A. 1991. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 118: 633-637. https://doi.org/10.1016/S0022-3476(05)83393-1.
73. Warny M, Denie C, Delmee M, Lefebvre C. 1995. Gamma globulin administration in relapsing Clostridium difficile-induced pseudomembranous colitis with a defective antibody response to toxin A. Acta Clin Belg 50: 36-39. https://doi.org/10.1080/17843286.1995.11718419.
74. Kyne L, Warny M, Qamar A, Kelly CP. 2001. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357: 189-193. https://doi.org/10.1016/S0140-6736(00)03592-3.
75. Johnson S, Gerding DN, Janoff EN. 1992. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J Infect Dis 166: 1287-1294. https://doi.org/10.1093/infdis/166.6.1287.
76. Warny M, Vaerman JP, Avesani V, Delmée M. 1994. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 62: 384-389.
77. Salcedo J, Keates S, Pothoulakis C, Warny M, Castagliuolo I, LaMont JT, Kelly CP. 1997. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 41: 366-370. https://doi.org/10.1136/ gut.41.3.366.
78. Hassett J, Meyers S, McFarland L, Mulligan ME. 1995. Recurrent Clostridium difficile infection in a patient with selective IgG1 deficiency treated with intravenous immune globulin and Saccharomyces boulardii. Clin Infect Dis 20(Suppl 2): S266-S268. https://doi.org/10.1093/ clinids/20.Supplement_2.S266.
79. Wilcox M. 2004. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 53: 882-884. https://doi.org/10.1093/jac/dkh176.
80. Shah N, Shaaban H, Spira R, Slim J, Boghossian J. 2014. Intravenous immunoglobulin in the treatment of severe Clostridium difficile colitis. J Glob Infect Dis 6: 82-85. https://doi.org/10.4103/0974-777X.132053.
81. Jehangir A, Bennett K, Fareedy SB, Rettew A, Shaikh B, Qureshi A, Jehangir Q, Alweis R. 2015. Recurrent C. difficile in a patient with IgG deficiency. Case Rep Gastrointest Med 2015: 356293. https://doi.org/10.1155/2015/356293.
82. McPherson S, Rees CJ, Ellis R, Soo S, Panter SJ. 2006. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 49: 640-645. https:// doi.org/10.1007/s10350-006-0511-8.
83. Juang P, Skledar SJ, Zgheib NK, Paterson DL, Vergis EN, Shannon WD, Ansani NT, Branch RA. 2007. Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea. Am J Infect Control 35: 131-137. https://doi.org/10.1016/j.ajic.2006.06.007.
84. Bagdasarian N, Rao K, Malani PN. 2015. Diagnosis and treatment of Clostridium difficile in adults. JAMA 313: 398-408. https://doi.org/10.1001/jama.2014.17103.
85. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364: 422-431. https://doi.org/10.1056/NEJMoa0910812.
86. Ananthakrishnan AN. 2011. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 8: 17-26. https://doi.org/10.1038/nrgastro.2010.190.
87. Kelly CP. 2012. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect 18(Suppl 6): 21-27. https://doi.org/10.1111/1469-0691.12046.
88. Deakin LJ, Clare S, Fagan RP, Dawson LF, Pickard DJ, West MR, Wren BW, Fairweather NF, Dougan G, Lawley TD. 2012. The Clostridium difficile spo0A gene is a persistence and transmission factor. Infect Immun 80: 2704-2711. https://doi.org/10.1128/IAI.00147-12.
89. Louie TJ, Byrne B, Emery J, Ward L, Krulicki W, Nguyen D, Wu K, Cannon K. 2015. Differences of the fecal microflora with Clostridium difficile therapies. Clin Infect Dis 60: S91-S97. https://doi.org/10.1093/cid/ civ252.
90. Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M, Krulicki W. 2012. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 55: S132-S142. https://doi.org/10.1093/cid/cis338.
91. Rea MC, Dobson A, O’Sullivan O, Crispie F, Fouhy F, Cotter PD, Shanahan F, Kiely B, Hill C, Ross RP. 2011. Effect of broad-and narrowspectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A 108: 4639-4644. https://doi.org/10.1073/pnas.1001224107.
92. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. 2013. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368: 407-415. https:// doi.org/10.1056/NEJMoa1205037.
93. Seekatz AM, Aas J, Gessert CE, Rubin TA, Saman DM, Bakken JS, Young VB. 2014. Recovery of the gut microbiome following fecal microbiota transplantation. mBio 5: e00893-14. https://doi.org/10.1128/mBio.00893-14.
94. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. 2010. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 44: 354-360. https://doi.org/10.1097/MCG.0b013e3181c87e02.
95. Weingarden A, González A, Vázquez-Baeza Y, Weiss S, Humphry G, Berg-Lyons D, Knights D, Unno T, Bobr A, Kang J, Khoruts A, Knight R, Sadowsky MJ. 2015. Dynamic changes in short-and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection. Microbiome 3: 10. https://doi.org/10.1186/s40168-015-0070-0.
96. Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, Raisen C, Goulding D, Rad R, Schreiber F, Brandt C, Deakin LJ, Pickard DJ, Duncan SH, Flint HJ, Clark TG, Parkhill J, Dougan G. 2012. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 8: e1002995. https://doi.org/10.1371/journal.ppat.1002995.
97. Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, Daigneault MC, Brown EM, Schroeter K, Allen-Vercoe E. 2013. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: "RePOOPulating" the gut. Microbiome 1: 3. https://doi.org/10.1186/2049-2618-1-3.
98. Emanuelsson F, Claesson BEB, Ljungström L, Tvede M, Ung K-A. 2014. Faecal microbiota transplantation and bacteriotherapy for recurrent Clostridium difficile infection: a retrospective evaluation of 31 patients. Scand J Infect Dis 46: 89-97. https://doi.org/10.3109/00365548.2013.858181.
99. Tvede M, Rask-Madsen J. 1989. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 333: 1156-1160. https://doi.org/10.1016/S0140-6736(89)92749-9.
100. Khanna S, Pardi DS, Kelly CR, Kraft CS, Dhere T, Henn MR, Lombardo M, Vulic M, Ohsumi T, Winkler J, Pindar C, McGovern BH, Pomerantz RJ, Aunins JG, Cook DN, Hohmann EL. 2016. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis 214: 173-181. https://doi.org/10.1093/infdis/jiv766.
101. Seres Therapeutics Inc. 2016. Seres Therapeutics announces interim results from SER-109 phase 2 ECOSPOR study in multiply recurrent Clostridium difficile infection. Press release. Seres Therapeutics Inc Cambridge, MA. http://ir.serestherapeutics.com/phoenix.zhtml?c=254006&p=irol-newsArticle&ID=2190006.
102. Li M, Liang P, Li Z, Wang Y, Zhang G, Gao H, Wen S, Tang L. 2015. Fecal microbiota transplantation and bacterial consortium transplantation have comparable effects on the re-establishment of mucosal barrier function in mice with intestinal dysbiosis. Front Microbiol 6: 692. https:// doi.org/10.3389/fmicb.2015.00692.
103. Lau CSM, Chamberlain RS. 2016. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and metaanalysis. Int J Gen Med 9: 27-37. https://doi.org/10.2147/IJGM.S98280.
104. Johnson S, Maziade PJ, McFarland LV, Trick W, Donskey C, Currie B, Low DE, Goldstein EJC. 2012. Is primary prevention of Clostridium difficile infection possible with specific probiotics? Int J Infect Dis 16: e78627-e792. https://doi.org/10.1016/j.ijid.2012.06.005.
105. Dendukuri N, Costa V, McGregor M, Brophy JM. 2005. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 173: 167-170. https://doi.org/10.1503/cmaj.050350.
106. Allen SJ, Wareham K, Wang D, Bradley C, Hutchings H, Harris W, Dhar A, Brown H, Foden A, Gravenor MB, Mack D. 2013. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 382: 1249-1257. https://doi.org/10.1016/S0140-6736(13)61218-0.
107. Dendukuri N, Brophy J. 2007. Inappropriate use of meta-analysis to estimate efficacy of probiotics. Am J Gastroenterol 102: 201. https:// doi.org/10.1111/j.1572-0241.2007.00916.x.
108. Lewis S. 2007. Response to "Meta-analysis of probiotics for the prevention of antibiotic-associated diarrhea and the treatment of Clostridium difficile disease". Am J Gastroenterol 2006;101: 812-822. Am J Gastroenterol 102: 201-202. https://doi.org/10.1111/j.1572-0241.2007.00916.x.
109. Pillai A, Nelson R. 2008. Probiotics for treatment of Clostridium difficileassociated colitis in adults. Cochrane Database Syst Rev 1: CD004611. https://doi.org/10.1002/14651858.CD004611.pub2.
110. Mcfarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL, Noorani Z, Harrington G, Rubin M, Greenwald D. 1994. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271: 1913-1918. https://doi.org/10.1001/ jama.1994.03510480037031.
111. Reeves AE, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, Young VB. 2011. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile infection. Gut Microbes 2: 145-158. https://doi.org/10.4161/gmic.2.3.16333.
112. Schubert AM, Sinani H, Schloss PD. 2015. Antibiotic-induced alterations of the murine gut microbiota and subsequent effects on colonization resistance against Clostridium difficile. mBio 6: e00974-15. https:// doi.org/10.1128/mBio.00974-15.
113. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, Littmann E, van den Brink MRM, Jenq RR, Taur Y, Sander C, Cross J, Toussaint NC, Xavier JB, Pamer EG. 2015. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517: 205-208. https://doi.org/10.1038/nature13828.
114. Manges AR, Labbe A, Loo VG, Atherton JK, Behr MA, Masson L, Tellis PA, Brousseau R. 2010. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficileassociated disease. J Infect Dis 202: 1877-1884. https://doi.org/10.1086/657319.
115. Schubert AM, Rogers MA, Ring C, Mogle J, Petrosino JP, Young VB, Aronoff DM, Schloss PD. 2014. Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls. mBio 5: e01021-14. https://doi.org/10.1128/ mBio.01021-14.
116. Shahinas D, Silverman M, Sittler T, Chiu C, Kim P, Allen-Vercoe E, Weese S, Wong A, Pillai DR. 2012. Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing. mBio 3: e00338-12. https://doi.org/10.1128/mBio.00338-12.
117. Song Y, Garg S, Girotra M, Maddox C, von Rosenvinge EC, Dutta A, Dutta S, Fricke WF. 2013. Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLoS One 8: e81330. https://doi.org/10.1371/journal.pone.0081330.
118. Antharam VC, Li EC, Ishmael A, Sharma A, Mai V, Rand KH, Wang GP. 2013. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol 51: 2884-2892. https://doi.org/10.1128/JCM.00845-13.
119. Dutta SK, Girotra M, Garg S, Dutta A, von Rosenvinge EC, Maddox C, Song Y, Bartlett JG, Vinayek R, Fricke WF. 2014. Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 12: 1572-1576. https://doi.org/10.1016/j.cgh.2013.12.032.
120. Stecher B. 2013. Finding a sugary foothold: how antibiotics pave the way for enteric pathogens. Cell Host Microbe 14: 225-227. https:// doi.org/10.1016/j.chom.2013.08.008.
121. Theriot CM, Koenigsknecht MJ, Carlson PEJ, Hatton GE, Nelson AM, Li B, Huffnagle GB, Li J, Young VB. 2014. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun 5: 3114. https://doi.org/10.1038/ncomms4114.
122. Antunes LCM, Han J, Ferreira RBR, Lolic P, Borchers CH, Finlay BB. 2011. Effect of antibiotic treatment on the intestinal metabolome. Antimicrob Agents Chemother 55: 1494-1503. https://doi.org/10.1128/ AAC.01664-10.
123. Ng KM, Ferreyra J, Higginbottom SK, Lynch JB, Kashyap PC, Gopinath S, Naidu N, Choudhury B, Weimer BC, Monack DM, Sonnenburg JL. 2013. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 502: 96-99. https://doi.org/10.1038/ nature12503.
124. Ferreyra JA, Wu KJ, Hryckowian AJ, Bouley DM, Weimer BC, Sonnenburg JL. 2014. Gut microbiota-produced succinate promotes C. difficile infection after antibiotic treatment or motility disturbance. Cell Host Microbe 16: 770-777. https://doi.org/10.1016/j.chom.2014.11.003.
125. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. 1998. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 351: 633-636. https://doi.org/10.1016/ S0140-6736(97)08062-8.
126. Nagaro KJ, Phillips ST, Cheknis AK, Sambol SP, Zukowski WE, Johnson S, Gerding DN. 2013. Nontoxigenic Clostridium difficile protects hamsters against challenge with historic and epidemic strains of toxigenic BI/NAP1/027 C. difficile. Antimicrob Agents Chemother 57: 5266-5270. https://doi.org/10.1128/AAC.00580-13.
127. Sambol SP, Merrigan MM, Tang JK, Johnson S, Gerding DN. 2002. Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis 186: 1781-1789. https://doi.org/10.1086/345676.
128. Villano SA, Seiberling M, Tatarowicz W, Monnot-Chase E, Gerding DN. 2012. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother 56: 5224-5229. https://doi.org/10.1128/AAC.00913-12.
129. Gerding DN, Meyer T, Lee C, Cohen SH, Murthy UK, Poirier A, Van Schooneveld TC, Pardi DS, Ramos A, Barron MA, Chen H, Villano S. 2015. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C difficile infection: a randomized clinical trial. JAMA 313: 1719-1727. https://doi.org/10.1001/jama.2015.3725.
130. Brouwer MSM, Roberts AP, Hussain H, Williams RJ, Allan E, Mullany P. 2013. Horizontal gene transfer converts non-toxigenic Clostridium difficile strains into toxin producers. Nat Commun 4: 2601. https://doi.org/10.1038/ncomms3601.
131. Ridlon JM. 2005. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47: 241-259. https://doi.org/10.1194/jlr.R500013-JLR200.
132. Wilson KH. 1983. Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination. J Clin Microbiol 18: 1017-1019.
133. Giel JL, Sorg JA, Sonenshein AL, Zhu J. 2010. Metabolism of bile salts in mice influences spore germination in Clostridium difficile. PLoS One 5: e8740. https://doi.org/10.1371/journal.pone.0008740.
134. Jump RLP, Polinkovsky A, Hurless K, Sitzlar B, Eckart K, Tomas M, Deshpande A, Nerandzic MM, Donskey CJ. 2014. Metabolomics analysis identifies intestinal microbiota-derived biomarkers of colonization resistance in clindamycin-treated mice. PLoS One 9: e101267. https:// doi.org/10.1371/journal.pone.0101267.
135. Allegretti JR, Kearney S, Li N, Bogart E, Bullock K, Gerber GK, Bry L, Clish CB, Alm E, Korzenik JR. 2016. Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment Pharmacol Ther 43: 1142-1153. https://doi.org/10.1111/apt.13616.
136. Weingarden AR, Chen C, Bobr A, Yao D, Lu Y, Nelson VM, Sadowsky MJ, Khoruts A. 2014. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol 306: G310-G319. https://doi.org/10.1152/ajpgi.00282.2013.
137. Schoster A, Kokotovic B, Permin A, Pedersen PD, Bello FD, Guardabassi L. 2013. In vitro inhibition of Clostridium difficile and Clostridium perfringens by commercial probiotic strains. Anaerobe 20: 36-41. https://doi.org/10.1016/j.anaerobe.2013.02.006.
138. Tejero-Sariñena S, Barlow J, Costabile A, Gibson GR, Rowland I. 2012. In vitro evaluation of the antimicrobial activity of a range of probiotics against pathogens: evidence for the effects of organic acids. Anaerobe 18: 530-538. https://doi.org/10.1016/j.anaerobe.2012.08.004.
139. Trejo FM, Minnaard J, Perez PF, De Antoni GL. 2006. Inhibition of Clostridium difficile growth and adhesion to enterocytes by Bifidobacterium supernatants. Anaerobe 12: 186-193. https://doi.org/10.1016/ j.anaerobe.2006.03.004.
140. Geeraerts S, Ducatelle R, Haesebrouck F, Van Immerseel F. 2015. Bacillus amyloliquefaciens as prophylactic treatment for Clostridium difficile-associated disease in a mouse model. J Gastroenterol Hepatol 30: 1275-1280. https://doi.org/10.1111/jgh.12957.
141. Rea MC, Clayton E, O’Connor PM, Shanahan F, Kiely B, Ross RP, Hill C. 2007. Antimicrobial activity of lacticin 3147 against clinical Clostridium difficile strains. J Med Microbiol 56: 940-946. https://doi.org/10.1099/ jmm.0.47085-0.
142. Ryan MP, Rea MC, Hill C, Ross RP. 1996. An application in cheddar cheese manufacture for a strain of Lactococcus lactis producing a novel broad-spectrum bacteriocin, lacticin 3147. Appl Environ Microbiol 62: 612-619.
143. Rea MC, Sit CS, Clayton E, O’Connor PM, Whittal RM, Zheng J, Vederas JC, Ross RP, Hill C. 2010. Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc Natl Acad Sci U S A 107: 9352-9357. https://doi.org/10.1073/pnas.0913554107.
144. Rea MC, Alemayehu D, Casey PG, O’Connor PM, Lawlor PG, Walsh M, Shanahan F, Kiely B, Ross RP, Hill C. 2014. Bioavailability of the anticlostridial bacteriocin thuricin CD in gastrointestinal tract. Microbiology 160: 439-445. https://doi.org/10.1099/mic.0.068767-0.
145. Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C. 1996. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 64: 5225-5232.
146. Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C. 1999. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 67: 302-307.
147. Corthier G, Lucas F, Jouvert S, Castex F. 1992. Effect of oral Saccharomyces boulardii treatment on the activity of Clostridium difficile toxins in mouse digestive tract. Toxicon 30: 1583-1589. https://doi.org/10.1016/0041-0101(92)90030-9.
148. Qamar A, Aboudola S, Warny M, Michetti P, Pothoulakis C, LaMont JT, Kelly CP. 2001. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 69: 2762-2765. https://doi.org/10.1128/IAI.69.4.2762-2765.2001.
149. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, Boatright N, Stack AM, Lowy I, Graziano R, Molrine D, Ambrosino DM, Thomas WD. 2006. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 74: 6339-6347. https://doi.org/10.1128/IAI.00982-06.
150. Anosova NG, Cole LE, Li L, Zhang J, Brown AM, Mundle S, Zhang J, Ray S, Ma F, Garrone P, Bertraminelli N, Kleanthous H, Anderson SF. 2015. A combination of three fully human toxin A-and toxin B-specific monoclonal antibodies protects against challenge with highly virulent epidemic strains of Clostridium difficile in the hamster model. Clin Vaccine Immunol 22: 711-725. https://doi.org/10.1128/CVI.00763-14.
151. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WDJ, Leney M, Sloan S, Hay CA, Ambrosino DM. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362: 197-205. https://doi.org/10.1056/NEJMoa0907635.
152. Buts JP, Bernasconi P, Vaerman JP, Dive C. 1990. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 35: 251-256. https://doi.org/10.1007/BF01536771.
153. Martins FS, Silva AA, Vieira AT, Barbosa FH, Arantes RM, Teixeira MM, Nicoli JR. 2009. Comparative study of Bifidobacterium animalis, Escherichia coli, Lactobacillus casei and Saccharomyces boulardii probiotic properties. Arch Microbiol 191: 623-630. https://doi.org/10.1007/ s00203-009-0491-x.
154. Rodrigues ACP, Cara DC, Fretez SHGG, Cunha FQ, Vieira EC, Nicoli JR, Vieira LQ. 2000. Saccharomyces boulardii stimulates sIgA production and the phagocytic system of gnotobiotic mice. J Appl Microbiol 89: 404-414. https://doi.org/10.1046/j.1365-2672.2000.01128.x.
155. Generoso SV, Viana ML, Santos RG, Arantes RME, Martins FS, Nicoli JR, Machado JAN, Correia MITD, Cardoso VN. 2011. Protection against increased intestinal permeability and bacterial translocation induced by intestinal obstruction in mice treated with viable and heat-killed Saccharomyces boulardii. Eur J Nutr 50: 261-269. https://doi.org/10.1007/s00394-010-0134-7.
156. Roller M, Rechkemmer G, Watzl B. 2004. Prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis modulates intestinal immune functions in rats. J Nutr 134: 153-156.
157. Sharma R, Kapila R, Dass G, Kapila S. 2014. Improvement in Th1/Th2 immune homeostasis, antioxidative status and resistance to pathogenic E. coli on consumption of probiotic Lactobacillus rhamnosus fermented milk in aging mice. Age 36: 9686. https://doi.org/10.1007/ s11357-014-9686-4.
158. Galdeano CM, Perdigo G. 2006. The probiotic bacterium Lactobacillus casei induces activation of the gut mucosal immune system through innate immunity. Clin Vaccine Immunol 13: 219-226. https://doi.org/10.1128/CVI.13.2.219-226.2006.
159. Kim YS, Ho SB. 2010. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep 12: 319-330. https://doi.org/10.1007/s11894-010-0131-2.
160. Johansson M, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC. 2008. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A 105: 15064-15069. https://doi.org/10.1073/pnas.0803124105.
161. Johansson M, Larsson JMH, Hansson GC. 2011. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci U S A 108: 4659-4665. https://doi.org/10.1073/pnas.1006451107.
162. Engevik M, Yacyshyn MB, Engevik K, Wang J, Darien B, Hassett DJ, Yacyshyn BR, Worrell RT. 2015. Human Clostridium difficile infection: altered mucus production and composition. Am J Physiol Gastrointest Liver Physiol 308: G510-G524. https://doi.org/10.1152/ ajpgi.00091.2014.
163. Eveillard M, Fourel V, Barc MC, Kernéis S, Coconnier MH, Karjalainen T, Bourlioux P, Servin A. 1993. Identification and characterization of adhesive factors of Clostridium difficile involved in adhesion to human colonic enterocyte-like Caco-2 and mucus-secreting HT29 cells in culture. Mol Microbiol 7: 371-381. https://doi.org/10.1111/j.1365-2958.1993.tb01129.x.
164. Calabi E, Calabi F, Phillips AD, Fairweather NF, Neil F. 2002. Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues. Infect Immun 70: 5770-5778. https://doi.org/10.1128/IAI.70.10.5770-5778.2002.
165. Krivan HC, Clark GF, Smith DF, Wilkins TD. 1986. Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gala1-3Galb1-4GlcNAc. Infect Immun 53: 573-581.
166. Smith J, Cooke DL, Hyde S, Borriello SP, Long RG. 1997. Clostridium difficile toxin A binding to human intestinal epithelial cells. J Med Microbiol 46: 953-958. https://doi.org/10.1099/00222615-46-11-953.
167. Branka JE, Vallette G, Jarry A, Bou-Hana C, Lemarre P, Van PN, Laboisse CL. 1997. Early functional effects of Clostridium difficile toxin A on human colonocytes. Gastroenterology 112: 1887-1894. https://doi.org/10.1053/gast.1997.v112.pm9178681.
168. Mattar AF, Teitelbaum DH, Drongowski RA, Yongyi F, Harmon CM, Coran AG. 2002. Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatr Surg Int 18: 586-590. https:// doi.org/10.1007/s00383-002-0855-7.
169. Mack D, Ahrne S, Hyde L, Wei S, Hollingsworth M. 2003. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 52: 827-833. https://doi.org/10.1136/gut.52.6.827.
170. Wang L, Cao H, Liu L, Wang B, Walker WA, Acra SA, Yan F. 2014. Activation of epidermal growth factor receptor mediates mucin production stimulated by p40, a Lactobacillus rhamnosus GG-derived protein. J Biol Chem 289: 20234-20244. https://doi.org/10.1074/ jbc.M114.553800.
171. Zhang W, Zhu Y, Yang J, Yang G, Zhou D, Wang J. 2015. A selected Lactobacillus rhamnosus strain oromotes EGFR-independent Akt activation in an enterotoxigenic Escherichia coli K88-infected IPEC-J2 cell model. PLoS One 10: e0125717. https://doi.org/10.1371/ journal.pone.0125717.
172. Otte J-M, Podolsky DK. 2004. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 286: G613-G626. https://doi.org/10.1152/ ajpgi.00341.2003.
173. Caballero-Franco C, Keller K, Simone C, Chadee K. 2007. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 292: G315-G322.
174. Zanello G, Berri M, Dupont J, Sizaret PY, D’Inca R, Salmon H, Meurens F. 2011. Saccharomyces cerevisiae modulates immune gene expressions and inhibits ETEC-mediated ERK1/2 and p38 signaling pathways in intestinal epithelial cells. PLoS One 6: e18573. https://doi.org/10.1371/ journal.pone.0018573.
175. Schneider S-M, Girard-Pipau F, Filippi J, Hebuterne X, Moyse D, Hinojosa G-C, Pompei A, Rampal P. 2005. Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World J Gastroenterol 11: 6165-6169. https:// doi.org/10.3748/wjg.v11.i39.6165.
176. Gaudier E, Rival M, Buisine MP, Robineau I, Hoebler C. 2009. Butyrate enemas upregulate Muc genes expression but decrease adherent mucus thickness in mice colon. Physiol Res 58: 111-119.
177. Ouwehand A, Isolauri E, Kirjavainen PV, Salminen SJ. 1999. Adhesion of four Bifidobacterium strains to human intestinal mucus from subjects in different age groups. FEMS Microbiol Lett 172: 61-64. https://doi.org/10.1111/j.1574-6968.1999.tb13450.x.
178. Ouwehand A, Isolauri E, Kirjavainen PV, Tölkko S, Salminen SJ. 2000. The mucus binding of Bifidobacterium lactis Bb12 is enhanced in the presence of Lactobacillus GG and Lact. delbrueckii subsp. bulgaricus. Lett Appl Microbiol 30: 10-13. https://doi.org/10.1046/j.1472-765x.2000.00590.x.
179. Farquhar MG, Palade GE. 1963. Junctional complexes in various epithelia. J Cell Biol 17: 375-412. https://doi.org/10.1083/jcb.17.2.375.
180. Fanning AS, Jameson BJ, Lynne A, Anderson JM, Jesaitis LA, Melvin J. 1998. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J Biol Chem 273: 29745-29753. https://doi.org/10.1074/jbc.273.45.29745.
181. Madara JL. 1987. Intestinal absorptive cell tight junctions are linked to cytoskeleton. Am J Physiol 253: C171-C175.
182. Perez-Moreno M, Fuchs E. 2006. Catenins: keeping cells from getting their signals crossed. Dev Cell 11: 601-612. https://doi.org/10.1016/ j.devcel.2006.10.010.
183. Suzuki T, Yoshida S, Hara H. 2008. Physiological concentrations of short-chain fatty acids immediately suppress colonic epithelial permeability. Br J Nutr 100: 297-305. https://doi.org/10.1017/ S0007114508888733.
184. Peng L, Li Z-R, Green RS, Holzman IR, Lin J. 2009. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 139: 1619-1625. https://doi.org/10.3945/jn.109.104638.
185. Sultana R, McBain AJ, O’Neill CA. 2013. Strain-dependent augmentation of tight-junction barrier function in human primary epidermal keratinocytes by Lactobacillus and Bifidobacterium lysates. Appl Environ Microbiol 79: 4887-4894. https://doi.org/10.1128/AEM.00982-13.
186. Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P. 2000. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun 68: 5998-6004. https://doi.org/10.1128/IAI.68.10.5998-6004.2000.
187. Garcia Vilela E, De Lourdes De Abreu Ferrari M, Da Gama Torres HO, Guerra Pinto A, Carneiro Aguirre AC, Paiva Martins F, Andrade Goulart EM, Da Cunha AS. 2008. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn’s disease in remission. Scand J Gastroenterol 43: 842-848. https://doi.org/10.1080/00365520801943354.
188. Li M, Zhu L, Xie A, Yuan J. 2015. Oral administration of Saccharomyces boulardii ameliorates carbon tetrachloride-induced liver fibrosis in rats via reducing intestinal permeability and modulating gut microbial composition. Inflammation 38: 170-179. https://doi.org/10.1007/ s10753-014-0019-7.
189. Justino PFC, Melo LFM, Nogueira AF, Costa JVG, Silva LMN, Santos CM, Mendes WO, Costa MR, Franco AX, Lima AA, Ribeiro RA, Souza MHLP, Soares PMG. 2014. Treatment with Saccharomyces boulardii reduces the inflammation and dysfunction of the gastrointestinal tract in 5-fluorouracil-induced intestinal mucositis in mice. Br J Nutr 111: 1611-1621. https://doi.org/10.1017/S0007114513004248.
190. Mumy KL, Chen X, Kelly CP, McCormick BA. 2008. Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events. Am J Physiol Gastrointest Liver Physiol 294: G599-G609. https://doi.org/10.1152/ajpgi.00391.2007.
191. Martz SL, McDonald JAK, Sun J, Zhang YG, Gloor GB, Noordhof C, He SM, Gerbaba TK, Blennerhassett M, Hurlbut DJ, Allen-Vercoe E, Claud EC, Petrof EO. 2015. Administration of defined microbiota is protective in a murine Salmonella infection model. Sci Rep 5: 16094. https:// doi.org/10.1038/srep16094.
192. Hsieh C-Y, Osaka T, Moriyama E, Date Y, Kikuchi J, Tsuneda S. 2015. Strengthening of the intestinal epithelial tight junction by Bifidobacterium bifidum. Physiol Rep 3: e12327. https://doi.org/10.14814/ phy2.12327.
193. Wang B, Huang Q, Zhang W, Li N, Li J. 2011. Lactobacillus plantarum prevents bacterial translocation in rats following ischemia and reperfusion injury. Dig Dis Sci 56: 3187-3194. https://doi.org/10.1007/s10620-011-1747-2.
194. Madan R, Petri WA. 2012. Immune responses to Clostridium difficile infection. Trends Mol Med 18: 658-666. https://doi.org/10.1016/ j.molmed.2012.09.005.
195. Riquelme AJ, Calvo MA, Guzmán AM, Depix MS, García P, Pérez C, Arrese M, Labarca JA. 2003. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol 36: 41-43. https://doi.org/10.1097/00004836-200301000-00013.
196. Vahabnezhad E, Mochon A, Wozniak L, Ziring D. 2013. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol 47: 437-439. https://doi.org/10.1097/MCG.0b013e318279abf0.
197. Loftus E. 2004. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126: 1504-1517. https://doi.org/10.1053/j.gastro.2004.01.063.
198. Kappelman MD, Rifas-Shiman SL, Kleinman K, Ollendorf D, Bousvaros A, Grand RJ, Finkelstein JA. 2007. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 5: 1424-1429. https://doi.org/10.1016/ j.cgh.2007.07.012.
199. Anderson CA, Boucher G, Lees CW, Franke A, D’Amato M, Taylor KD, Lee JC, Goyette P, Imielinski M, Latiano A, Lagacé C, Scott R, Amininejad L, Bumpstead S, Baidoo L, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Colombel J-F, Denson LA, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann RSN, Floyd JAB, Florin T, Franchimont D, Franke L, Georges M, Glas J, Glazer NL, Guthery SL, Haritunians T, Hayward NK, Hugot J-P, Jobin G, Laukens D, Lawrance I, Lémann M, Levine A, Libioulle C, Louis E, McGovern DP, Milla M, Montgomery GW, Morley KI, Mowat C, et al. 2011. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 43: 246-252. https://doi.org/10.1038/ng.764.
200. Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H. 2015. Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. World J Gastroenterol 21: 21-46. https:// doi.org/10.3748/wjg.v21.i1.21.
201. Loddenkemper C. 2009. Diagnostic standards in the pathology of inflammatory bowel disease. Dig Dis 27: 576-583. https://doi.org/10.1159/000233301.
202. Choi C-HR, Ignjatovic-Wilson A, Askari A, Lee GH, Warusavitarne J, Moorghen M, Thomas-Gibson S, Saunders BP, Rutter MD, Graham TA, Hart AL. 2015. Low-grade dysplasia in ulcerative colitis: risk factors for developing high-grade dysplasia or colorectal cancer. Am J Gastroenterol 110: 1461-1471. https://doi.org/10.1038/ajg.2015.248.
203. Thomas T, Abrams KA, Robinson RJ, Mayberry JF. 2007. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther 25: 657-668. https://doi.org/10.1111/j.1365-2036.2007.03241.x.
204. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. 2001. The prevalence of extraintestinal diseases in inflammatory bowel disease: a populationbased study. Am J Gastroenterol 96: 1116-1122. https://doi.org/10.1111/j.1572-0241.2001.03756.x.
205. Reif S, Klein I, Lubin F, Farbstein M, Hallak A, Gilat T. 1997. Pre-illness dietary factors in inflammatory bowel disease. Gut 40: 754-760. https:// doi.org/10.1136/gut.40.6.754.
206. Danese S, Sans M, Fiocchi C. 2004. Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev 3: 394-400. https://doi.org/10.1016/j.autrev.2004.03.002.
207. Andersson RE, Olaison G, Tysk C, Ekbom A. 2001. Appendectomy and protection against ulcerative colitis. N Engl J Med 344: 808-814. https:// doi.org/10.1056/NEJM200103153441104.
208. Harries AD, Baird A, Rhodes J. 1982. Non-smoking: a feature of ulcerative colitis. Br Med J 284: 706. https://doi.org/10.1136/ bmj.284.6317.706.
209. Sartor RB. 2006. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 3: 390-407. https://doi.org/10.1038/ncpgasthep0528.
210. de Souza HSP, Fiocchi C. 2016. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol 13: 13-27. https:// doi.org/10.1038/nrgastro.2015.186.
211. Michielan A, D’Incà R. 2015. Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut. Mediators Inflamm 2015: 628157. https://doi.org/10.1155/2015/628157.
212. UK IBD Genetics Consortium, Wellcome Trust Case Control Consortium 2. 2009. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet 41: 1330-1334. https://doi.org/10.1038/ng.483.
213. Ho G-T, Nimmo ER, Tenesa A, Fennell J, Drummond H, Mowat C, Arnott ID, Satsangi J. 2005. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology 128: 288-296. https://doi.org/10.1053/ j.gastro.2004.11.019.
214. Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, Stange E, Herfarth H, Schoelmerich J, Gregor M, Walker S, Cascorbi I, Roots I, Brinkmann U, Zanger UM, Eichelbaum M. 2003. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 124: 26-33. https://doi.org/10.1053/ gast.2003.50010.
215. Van der Sluis M, De Koning BAE, De Bruijn ACJM, Velcich A, Meijerink JPP, Van Goudoever JB, Buller HA, Dekker J, Van Seuningen I, Renes IB, Einerhand AWC. 2006. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131: 117-129. https://doi.org/10.1053/j.gastro.2006.04.020.
216. Lennon G, Balfe Á, Early H, Devane LA, Lavelle A, Winter DC, Coffey JC, O’Connell PR. 2014. Influences of the colonic microbiome on the mucous gel layer in ulcerative colitis. Gut Microbes 5: 277-285. https:// doi.org/10.4161/gmic.28793.
217. Png CW, Linden SK, Gilshenan KS, Zoetendal EG, McSweeney CS, Sly LI, McGuckin MA, Florin TH. 2010. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol 105: 2420-2428. https://doi.org/10.1038/ ajg.2010.281.
218. Wlodarska M, Thaiss CA, Nowarski R, Henao-Mejia J, Zhang J, Brown EM, Frankel G, Levy M, Katz MN, Philbrick WM, Elinav E, Finlay BB. 2014. NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion. Cell 156: 1045-1059. https:// doi.org/10.1016/j.cell.2014.01.026.
219. Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ, Peaper DR, Bertin J, Eisenbarth SC, Gordon JI, Flavell RA. 2011. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145: 745-757. https://doi.org/10.1016/j.cell.2011.04.022.
220. Alipour M, Zaidi D, Valcheva R, Jovel J, Martínez I, Sergi C, Walter J, Mason AL, Wong GK-S, Dieleman LA, Carroll MW, Huynh HQ, Wine E. 2016. Mucosal barrier depletion and loss of bacterial diversity are primary abnormalities in paediatric ulcerative colitis. J Crohns Colitis 10: 462-471. https://doi.org/10.1093/ecco-jcc/jjv223.
221. Johansson MEV, Gustafsson JK, Holmén-Larsson J, Jabbar KS, Xia L, Xu H, Ghishan FK, Carvalho FA, Gewirtz AT, Sjövall H, Hansson GC. 2014. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut 63: 281-291. https://doi.org/10.1136/gutjnl-2012-303207.
222. Fava F, Danese S. 2011. Intestinal microbiota in inflammatory bowel disease: friend of foe? World J Gastroenterol 17: 557-566. https:// doi.org/10.3748/wjg.v17.i5.557.
223. Ling Z, Liu X, Jia X, Cheng Y, Luo Y, Yuan L, Wang Y, Zhao C, Guo S, Li L, Xu X, Xiang C. 2014. Impacts of infection with different toxigenic Clostridium difficile strains on faecal microbiota in children. Sci Rep 4: 7485. https://doi.org/10.1038/srep07485.
224. Sartor RB, Mazmanian SK. 2012. Intestinal microbes in inflammatory bowel diseases. Am J Gastroenterol Suppl 1: 15-21. https://doi.org/10.1038/ajgsup.2012.4.
225. Giaffer M, Holdsworth C, Duerden B. 1992. Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut 33: 646-650. https://doi.org/10.1136/gut.33.5.646.
226. Bullock NR, Booth JCL, Gibson GR. 2004. Comparative composition of bacteria in the human intestinal microflora during remission and active ulcerative colitis. Curr Issues Intest Microbiol 5: 59-64.
227. Lathrop SK, Bloom SM, Rao SM, Nutsch K, Lio C-W, Santacruz N, Peterson DA, Stappenbeck TS, Hsieh C-S. 2011. Peripheral education of the immune system by colonic commensal microbiota. Nature 478: 250-254. https://doi.org/10.1038/nature10434.
228. Round JL, Mazmanian SK. 2009. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 9: 313-324. https://doi.org/10.1038/nri2515.
229. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, Rennick DM, Sartor RB. 1998. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 66: 5224-5231.
230. Dianda L, Hanby A, Wright N, Sebesteny A, Hayday A, Owen MJ. 1997. T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol 150: 91-97.
231. Hart AL, Al-Hassi HO, Rigby RJ, Bell SJ, Emmanuel A, Knight SC, Kamm MA, Stagg AJ. 2005. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 129: 50-65. https:// doi.org/10.1053/j.gastro.2005.05.013.
232. Selby WS, Janossy G, Bofill M, Jewell DP. 1984. Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistological and cell isolation techniques. Gut 25: 32-40. https:// doi.org/10.1136/gut.25.1.32.
233. Zimmerman NP, Vongsa RA, Wendt MK, Dwinell MB. 2008. Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. Inflamm Bowel Dis 14: 1000-1011. https://doi.org/10.1002/ibd.20480.
234. Singh UP, Singh NP, Murphy EA, Price RL, Fayad R, Nagarkatti M, Nagarkatti PS. 2016. Chemokine and cytokine levels in inflammatory bowel disease patients. Cytokine 77: 44-49. https://doi.org/10.1016/ j.cyto.2015.10.008.
235. Wurbel M, McIntire MG, Dwyer P, Fiebiger E. 2011. CCL25/CCR9 interactions regulate large intestinal inflammation in a murine model of acute colitis. PLoS One 6: e16442. https://doi.org/10.1371/ journal.pone.0016442.
236. Roda G, Marocchi M, Sartini A, Roda E. 2011. Cytokine networks in ulcerative colitis. Ulcers 2011: 391787. https://doi.org/10.1155/2011/391787.
237. Sands BE, Kaplan GG. 2007. The role of TNF-alpha in ulcerative colitis. J Clin Pharmacol 47: 930-941. https://doi.org/10.1177/0091270007301623.
238. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, Vilien M, Strom M, Danielsson A, Verbaan H, Hellstrom PM, Magnuson A, Curman B. 2005. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebocontrolled study. Gastroenterology 128: 1805-1811. https://doi.org/10.1053/j.gastro.2005.03.003.
239. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, Yang Z, Exley M, Kitani A, Blumberg RS, Mannon P, Strober W. 2004. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 113: 1490-1497. https://doi.org/10.1172/JCI19836.
240. Wang P, Lu Y, Wen Y, Yu D, Ge L, Dong W, Xiang L, Shao J. 2013. IL-16 induces intestinal inflammation via PepT1 upregulation in a pufferfish model: new insights into the molecular mechanism of inflammatory bowel disease. J Immunol 191: 1413-1427. https://doi.org/10.4049/ jimmunol.1202598.
241. Seegert D, Rosenstiel P, Pfahler H, Pfefferkorn P, Nikolaus S, Schreiber S. 2001. Increased expression of IL-16 in inflammatory bowel disease. Gut 48: 326-332. https://doi.org/10.1136/gut.48.3.326.
242. Di Sabatino A, Biancheri P, Rovedatti L, MacDonald TT, Corazza GR. 2012. New pathogenic paradigms in inflammatory bowel disease. Inflamm Bowel Dis 18: 368-371. https://doi.org/10.1002/ibd.21735.
243. Owaga E, Hsieh R-H, Mugendi B, Masuku S, Shih C-K, Chang J-S. 2015. Th17 cells as potential probiotic therapeutic targets in inflammatory bowel diseases. Int J Mol Sci 16: 20841-20858. https://doi.org/10.3390/ ijms160920841.
244. Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A. 2014. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 13: 3-10. https://doi.org/10.1016/j.autrev.2013.06.004.
245. Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, Mankertz J, Gitter AH, Bürgel N, Fromm M, Zeitz M, Fuss I, Strober W, Schulzke JD. 2005. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129: 550-564. https://doi.org/10.1053/j.gastro.2005.05.002.
246. Zenewicz LA, Antov A, Flavell RA. 2009. CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med 15: 199-207. https:// doi.org/10.1016/j.molmed.2009.03.002.
247. Ito R, Kita M, Shin-Ya M, Kishida T, Urano A, Takada R, Sakagami J, Imanishi J, Iwakura Y, Okanoue T, Yoshikawa T, Kataoka K, Mazda O. 2008. Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice. Biochem Biophys Res Commun 377: 12-16. https://doi.org/10.1016/j.bbrc.2008.09.019.
248. Kobayashi T, Okamoto S, Hisamatsu T, Kamada N, Chinen H, Saito R, Kitazume MT, Nakazawa A, Sugita A, Koganei K, Isobe K, Hibi T. 2008. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease. Gut 57: 1682-1689. https://doi.org/10.1136/ gut.2007.135053.
249. Sugihara T, Kobori A, Imaeda H, Tsujikawa T, Amagase K, Takeuchi K, Fujiyama Y, Andoh A. 2010. The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease. Clin Exp Immunol 160: 386-393. https://doi.org/10.1111/j.1365-2249.2010.04093.x.
250. Ogawa A, Andoh A, Araki Y, Bamba T, Fujiyama Y. 2004. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol 110: 55-62. https://doi.org/10.1016/ j.clim.2003.09.013.
251. Zhang Z, Zheng M, Bindas J, Schwarzenberger P, Kolls JK. 2006. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis 12: 382-388. https://doi.org/10.1097/01.MIB.0000218764.06959.91.
252. Fitzpatrick LR, Deml L, Hofmann C, Small JS, Groeppel M, Hamm S, Lemstra S, Leban J, Ammendola A. 2010. 4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease. Inflamm Bowel Dis 16: 1763-1777. https://doi.org/10.1002/ibd.21264.
253. Fitzpatrick LR, Small J, Doblhofer R, Ammendola A. 2012. Vidofludimus inhibits IL-17 and improves hapten-induced colitis in young rats by a unique dual mode of action. J Crohns Colitis 6: S15-S16. https://doi.org/10.1016/S1873-9946(12)60033-6.
254. Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Löfberg R. 2000. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 47: 404-409. https://doi.org/10.1136/ gut.47.3.404.
255. Verspaget HW, Peña A, Weterman IT, Lamers CB. 1988. Diminished neutrophil function in Crohn’s disease and ulcerative colitis identified by decreased oxidative metabolism and low superoxide dismutase content. Gut 29: 223-228. https://doi.org/10.1136/gut.29.2.223.
256. Hanai H, Takeuchi K, Iida T, Kashiwagi N, Saniabadi AR, Matsushita I, Sato Y, Kasuga N, Nakamura T. 2004. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig Dis Sci 49: 1438-1443. https:// doi.org/10.1023/B: DDAS.0000042243.47279.87.
257. Fournier BM, Parkos CA. 2012. The role of neutrophils during intestinal inflammation. Mucosal Immunol 5: 354-366. https://doi.org/10.1038/ mi.2012.24.
258. Ferretti S, Bonneau O, Dubois GR, Jones CE, Trifilieff A. 2003. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol 170: 2106-2112. https://doi.org/10.4049/ jimmunol.170.4.2106.
259. Kolaczkowska E, Kubes P. 2013. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 13: 159-175. https:// doi.org/10.1038/nri3399.
260. Zhang R, Ito S, Nishio N, Cheng Z, Suzuki H, Isobe K. 2011. Upregulation of Gr1+ CD11b+ population in spleen of dextran sulfate sodium administered mice works to repair colitis. Inflamm Allergy Drug Targets 10: 39-46. https://doi.org/10.2174/187152811794352114.
261. Kühl AA, Kakirman H, Janotta M, Dreher S, Cremer P, Pawlowski NN, Loddenkemper C, Heimesaat MM, Grollich K, Zeitz M, Farkas S, Hoffmann JC. 2007. Aggravation of different types of experimental colitis by depletion or adhesion blockade of neutrophils. Gastroenterology 133: 1882-1892. https://doi.org/10.1053/j.gastro.2007.08.073.
262. Natsui M, Kawasaki K, Takizawa H, Hayashi SI, Matsuda Y, Sugimura K, Seki K, Narisawa R, Sendo F, Asakura H. 1997. Selective depletion of neutrophils by a monoclonal antibody, RP-3, suppresses dextran sulphate sodium-induced colitis in rats. J Gastroenterol Hepatol 12: 801-808. https://doi.org/10.1111/j.1440-1746.1997.tb00375.x.
263. Lee A, Whyte MK, Haslett C. 1993. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukoc Biol 54: 283-288.
264. Cox G. 1996. IL-10 enhances resolution of pulmonary inflammation in vivo by promoting apoptosis of neutrophils. Am J Physiol 271: L566-L571.
265. Salamone G, Giordano M, Trevani A, Gamberale R, Vermeulen M, Schettinni J, Geffner J. 2001. Promotion of neutrophil apoptosis by TNF-alpha. J Immunol 166: 3476-3483. https://doi.org/10.4049/ jimmunol.166.5.3476.
266. Kucharzik T, Walsh SV, Chen J, Parkos CA, Nusrat A. 2001. Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. Am J Pathol 159: 2001-2009. https://doi.org/10.1016/S0002-9440(10)63051-9.
267. Adeyemi E, Hodgson H. 1992. Faecal elastase reflects disease activity in active ulcerative colitis. Scand J Gastroenterol 27: 139-142. https:// doi.org/10.3109/00365529209165434.
268. Nielsen OH, Munck LK. 2007. Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol 4: 160-170. https://doi.org/10.1038/ncpgasthep0696.
269. Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. 2010. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol 105: 501-523. https:// doi.org/10.1038/ajg.2009.727.
270. Fraser AG, Orchard TR, Jewell DP. 2002. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 50: 485-489. https://doi.org/10.1136/gut.50.4.485.
271. George J, Present DH, Pou R, Bodian C, Rubin PH. 1996. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 91: 1711-1714.
272. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJS, Present D, Sands BE, Colombel JF. 2005. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462-2476. https://doi.org/10.1056/NEJMoa050516.
273. Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R. 2011. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60: 780-787. https://doi.org/10.1136/ gut.2010.221127.
274. Sandborn WJ, Van Assche G, Reinisch W, Colombel J, D’Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB. 2012. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142: 257-265. https://doi.org/10.1053/j.gastro.2011.10.032.
275. Campbell S, Travis S, Jewell D. 2005. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 17: 79-84. https://doi.org/10.1097/00042737-200501000-00016.
276. Timmer A, McDonald J, Tsoulis D, Macdonald J. 2012. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 9: CD000478. https://doi.org/10.1002/14651858.CD000478.pub3.
277. Cima R. 2010. Timing and indications for colectomy in chronic ulcerative colitis: surgical consideration. Dig Dis 28: 501-507. https://doi.org/10.1159/000320409.
278. Navaneethan U, Shen B. 2010. Secondary pouchitis: those with identifiable etiopathogenetic or triggering factors. Am J Gastroenterol 105: 51-64. https://doi.org/10.1038/ajg.2009.530.
279. Wu H, Shen B. 2010. Pouchitis and pouch dysfunction. Med Clin North Am 94: 75-92. https://doi.org/10.1016/j.mcna.2009.08.014.
280. Angelberger S, Reinisch W, Makristathis A, Lichtenberger C, Dejaco C, Papay P, Novacek G, Trauner M, Loy A, Berry D. 2013. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol 108: 1620-1630. https://doi.org/10.1038/ajg.2013.257.
281. Rubin DT. 2013. Curbing our enthusiasm for fecal transplantation in ulcerative colitis. Am J Gastroenterol 108: 1631-1633. https://doi.org/10.1038/ajg.2013.279.
282. Gupta S, Allen-Vercoe E, Petrof EO. 2016. Fecal microbiota transplantation: in perspective. Therap Adv Gastroenterol 9: 229-239. https://doi.org/10.1177/1756283X15607414.
283. Kao D, Hotte N, Gillevet P, Madsen K. 2014. Fecal microbiota transplantation inducing remission in Crohn’s colitis and the associated changes in fecal microbial profile. J Clin Gastroenterol 48: 625-628. https:// doi.org/10.1097/MCG.0000000000000131.
284. Kump PK, Gröchenig H-P, Lackner S, Trajanoski S, Reicht G, Hoffmann KM, Deutschmann A, Wenzl HH, Petritsch W, Krejs GJ, Gorkiewicz G, Högenauer C. 2013. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis 19: 2155-2165. https:// doi.org/10.1097/MIB.0b013e31829ea325.
285. Rossen NG, Fuentes S, Van Der Spek MJ, Tijssen JG, Hartman JHA, Duflou A, Lowenberg M, Van Den Brink GR, Mathus-Vliegen EMH, De Vos WM, Zoetendal EG, D’Haens GR, Ponsioen CY. 2015. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 149: 110-118. https://doi.org/10.1053/j.gastro.2015.03.045.
286. Colman RJ, Rubin DT. 2014. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 8: 1569-1581. https://doi.org/10.1016/ j.crohns.2014.08.006.
287. Tsuda Y, Yoshimatsu Y, Aoki H, Nakamura K, Irie M, Fukuda K, Hosoe N, Takada N, Shirai K, Suzuki Y. 2007. Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy. Scand J Gastroenterol 42: 1306-1311. https:// doi.org/10.1080/00365520701396091.
288. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. 2003. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 22: 56-63. https://doi.org/10.1080/07315724.2003.10719276.
289. Eloe-Fadrosh EA, Brady A, Crabtree J, Drabek EF, Ma B, Mahurkar A, Ravel J, Haverkamp M, Fiorino AM, Botelho C, Andreyeva I, Hibberd PL, Fraser CM. 2015. Functional dynamics of the gut microbiome in elderly people during probiotic consumption. mBio 6: e00231-15. https:// doi.org/10.1128/mBio.00231-15.
290. De Preter V, Raemen H, Cloetens L, Houben E, Rutgeerts P, Verbeke K. 2008. Effect of dietary intervention with different pre-and probiotics on intestinal bacterial enzyme activities. Eur J Clin Nutr 62: 225-231. https://doi.org/10.1038/sj.ejcn.1602706.
291. Barc MC, Charrin-Sarnel C, Rochet V, Bourlioux F, Sandré C, Boureau H, Doré J, Collignon A. 2008. Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: influence of Saccharomyces boulardii. Anaerobe 14: 229-233. https:// doi.org/10.1016/j.anaerobe.2008.04.003.
292. Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, Puri P, Sterling RK, Luketic V, Stravitz RT, Siddiqui MS, Fuchs M, Thacker LR, Wade JB, Daita K, Sistrun S, White MB, Noble NA, Thorpe C, Kakiyama G, Pandak WM, Sikaroodi M, Gillevet PM. 2014. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther 39: 1113-1125. https:// doi.org/10.1111/apt.12695.
293. Bull-Otterson L, Feng W, Kirpich I, Wang Y, Qin X, Liu Y, Gobejishvili L, Joshi-Barve S, Ayvaz T, Petrosino J, Kong M, Barker D, McClain C, Barve S. 2013. Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS One 8: e53028. https://doi.org/10.1371/ journal.pone.0053028.
294. Everard A, Matamoros S, Geurts L, Delzenne NM, Cani PD. 2014. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. mBio 5: e01011-14. https://doi.org/10.1128/mBio.01011-14.
295. Al-Sadi R, Boivin M, Ma T. 2009. Mechanism of cytokine modulation of epithelial tight junction barrier. Front Biosci (Landmark Ed) 14: 2765-2778.
296. Lee JS, Tato CM, Joyce-Shaikh B, Gulan F, Cayatte C, Chen Y, Blumenschein WM, Judo M, Ayanoglu G, McClanahan TK, Li X, Cua DJ. 2015. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. Immunity 43: 727-738. https://doi.org/10.1016/ j.immuni.2015.09.003.
297. Roselli M, Finamore A, Nuccitelli S, Carnevali P, Brigidi P, Vitali B, Nobili F, Rami R, Garaguso I, Mengheri E. 2009. Prevention of TNBS-induced colitis by different Lactobacillus and Bifidobacterium strains is associated with an expansion of gamma delta T and regulatory T cells of intestinal intraepithelial lymphocytes. Inflamm Bowel Dis 15: 1526-1536. https://doi.org/10.1002/ibd.20961.
298. Mazzon E, Puzzolo D, Caputi AP, Cuzzocrea S. 2002. Role of IL-10 in hepatocyte tight junction alteration in mouse model of experimental colitis. Mol Med 8: 353-366.
299. Keubler LM, Buettner M, Häger C, Bleich A. 2015. A multihit model: colitis lessons from the interleukin-10-deficient mouse. Inflamm Bowel Dis 21: 1967-1975. https://doi.org/10.1097/MIB.0000000000000468.
300. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274. https://doi.org/10.1016/0092-8674(93)80068-P.
301. Latvala S, Miettinen M, Kekkonen RA, Korpela R, Julkunen I. 2011. Lactobacillus rhamnosus GG and Streptococcus thermophilus induce suppressor of cytokine signalling 3 (SOCS3) gene expression directly and indirectly via interleukin-10 in human primary macrophages. Clin Exp Immunol 165: 94-103. https://doi.org/10.1111/j.1365-2249.2011.04408.x.
302. Hart AL, Lammers K, Brigidi P, Vitali B, Rizzello F, Gionchetti P, Campieri M, Kamm MA, Knight SC, Stagg AJ. 2004. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 53: 1602-1609. https://doi.org/10.1136/gut.2003.037325.
303. Gad M, Ravn P, Soborg DA, Lund-Jensen K, Ouwehand AC, Jensen SS. 2011. Regulation of the IL-10/IL-12 axis in human dendritic cells with probiotic bacteria. FEMS Immunol Med Microbiol 63: 93-107. https:// doi.org/10.1111/j.1574-695X.2011.00835.x.
304. Tanabe S, Kinuta Y, Saito Y. 2008. Bifidobacterium infantis suppresses proinflammatory interleukin-17 production in murine splenocytes and dextran sodium sulfate-induced intestinal inflammation. Int J Mol Med 22: 181-185.
305. Zoumpopoulou G, Foligne B, Christodoulou K, Grangetteb C, Pot B, Tsakalidou E. 2008. Lactobacillus fermentum ACA-DC 179 displays probiotic potential in vitro and protects against trinitrobenzene sulfonic acid (TNBS)-induced colitis and Salmonella infection in murine models. Int J Food Microbiol 121: 18-26. https://doi.org/10.1016/ j.ijfoodmicro.2007.10.013.
306. Shida K, Nanno M, Nagata S. 2011. Flexible cytokine production by macrophages and T cells in response to probiotic bacteria: a possible mechanism by which probiotics exert multifunctional immune regulatory activities. Gut Microbes 2: 109-114. https://doi.org/10.4161/ gmic.2.2.15661.
307. Christensen HR, Frøkiaer H, Pestka JJ. 2002. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol 168: 171-178. https://doi.org/10.4049/jimmunol.168.1.171.
308. Zeuthen LH, Christensen HR. 2006. Lactic acid bacteria inducing a weak interleukin-12 and tumor necrosis factor alpha response in human dendritic cells inhibit strongly stimulating lactic acid bacteria but act synergistically with Gram-negative bacteria. Clin Vaccine Immunol 13: 365-375. https://doi.org/10.1128/CVI.13.3.365-375.2006.
309. Smith IM, Christensen JE, Arneborg N, Jespersen L. 2014. Yeast modulation of human dendritic cell cytokine secretion: an in vitro study. PLoS One 9: e96595. https://doi.org/10.1371/journal.pone.0096595.
310. Thomas S, Przesdzing I, Metzke D, Schmitz J, Radbruch A, Baumgart DC. 2009. Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation. Clin Exp Immunol 156: 78-87. https://doi.org/10.1111/j.1365-2249.2009.03878.x.
311. Lammers KM, Helwig U, Swennen E, Rizzello F, Venturi A, Caramelli E, Kamm MA, Brigidi P, Gionchetti P, Campieri M. 2002. Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am J Gastroenterol 97: 1182-1186. https://doi.org/10.1111/j.1572-0241.2002.05693.x.
312. van der Aa Kühle A, Skovgaard K, Jespersen L. 2005. In vitro screening of probiotic properties of Saccharomyces cerevisiae var. boulardii and food-borne Saccharomyces cerevisiae strains. Int J Food Microbiol 101: 29-39. https://doi.org/10.1016/j.ijfoodmicro.2004.10.039.
313. Adouard N, Foligné B, Dewulf J, Bouix M, Picque D, Bonnarme P. 2015. In vitro characterization of the digestive stress response and immunomodulatory properties of microorganisms isolated from smear-ripened cheese. Int J Food Microbiol 197: 98-107. https://doi.org/10.1016/ j.ijfoodmicro.2014.12.011.
314. Sougioultzis S, Simeonidis S, Bhaskar KR, Chen X, Anton PM, Keates S, Pothoulakis C, Kelly CP. 2006. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun 343: 69-76. https:// doi.org/10.1016/j.bbrc.2006.02.080.
315. Schlee M, Harder J, Köten B, Stange EF, Wehkamp J, Fellermann K. 2008. Probiotic lactobacilli and VSL#3 induce enterocyte β-defensin 2. Clin Exp Immunol 151: 528-535. https://doi.org/10.1111/j.1365-2249.2007.03587.x.
316. Imaoka A, Shima T, Kato K, Mizuno S, Uehara T, Matsumoto S, Setoyana H, Hara T, Umesaki Y. 2008. Anti-inflammatory activity of probiotic Bifidobacterium: enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells. World J Gastroenterol 14: 2511-2516. https:// doi.org/10.3748/wjg.14.2511.
317. Ghadimi D, Helwig U, Schrezenmeir J, Heller KJ, de Vrese M. 2012. Epigenetic imprinting by commensal probiotics inhibits the IL-23/IL-17 axis in an in vitro model of the intestinal mucosal immune system. J Leukoc Biol 92: 895-911. https://doi.org/10.1189/jlb.0611286.
318. Miyauchi E, Ogita T, Miyamoto J, Kawamoto S, Morita H, Ohno H, Suzuki T, Tanabe S. 2013. Bifidobacterium longum alleviates dextran sulfate sodium-induced colitis by suppressing IL-17A response: involvement of intestinal epithelial costimulatory molecules. PLoS One 8: e79735. https://doi.org/10.1371/journal.pone.0079735.
319. Chen L, Zou Y, Peng J, Lu F, Yin Y, Li F, Yang J. 2015. Lactobacillus acidophilus suppresses colitis-associated activation of the IL-23/Th17 axis. J Immunol Res 2015: 909514. https://doi.org/10.1155/2015/909514.
320. Ogita T, Tanii Y, Morita H, Suzuki T, Tanabe S. 2011. Suppression of Th17 response by Streptococcus thermophilus ST28 through induction of IFN-γ. Int J Mol Med 28: 817-822. https://doi.org/10.3892/ ijmm.2011.755.
321. Mañé J, Lorén V, Pedrosa E, Ojanguren I, Xaus J, Cabré E, Domènech E, Gassull MA. 2009. Lactobacillus fermentum CECT 5716 prevents and reverts intestinal damage on TNBS-induced colitis in mice. Inflamm Bowel Dis 15: 1155-1163. https://doi.org/10.1002/ibd.20908.
322. Yoon H, Yoon Y, Kim M, Chung M, Yum D. 2014. A probiotic preparation Duolac-Gold ameliorates dextran sulphate sodium-induced mouse colitis by downregulating the expression of IL-6. Toxicol Res 30: 27-32. https://doi.org/10.5487/TR.2014.30.1.027.
323. Lee HS, Han SY, Bae EA, Huh CS, Ahn YT, Lee JH, Kim DH. 2008. Lactic acid bacteria inhibit proinflammatory cytokine expression and bacterial glycosaminoglycan degradation activity in dextran sulfate sodiuminduced colitic mice. Int Immunopharmacol 8: 574-580. https://doi.org/10.1016/j.intimp.2008.01.009.
324. Vong L, Lorentz RJ, Assa A, Glogauer M, Sherman PM. 2014. Probiotic Lactobacillus rhamnosus inhibits the formation of neutrophil extracellular traps. J Immunol 192: 1870-1877. https://doi.org/10.4049/ jimmunol.1302286.
325. Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. 2010. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med 10: 13. https://doi.org/10.1186/1472-6882-10-13.
326. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon ATR. 1999. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354: 635-639. https://doi.org/10.1016/S0140-6736(98)06343-0.
327. Low D, Nguyen DD, Mizoguchi E. 2013. Animal models of ulcerative colitis and their application in drug research. Drug Des Devel Ther 7: 1341-1357. https://doi.org/10.2147/DDDT.S40107.
328. Hutton ML, Mackin KE, Chakravorty A, Lyras D. 2014. Small animal models for the study of Clostridium difficile disease pathogenesis. FEMS Microbiol Lett 352: 140-149. https://doi.org/10.1111/1574-6968.12367.
329. Chilton C, Freeman J. 2015. Predictive values of models of Clostridium difficile infection. Infect Dis Clin North Am 29: 163-177. https://doi.org/10.1016/j.idc.2014.11.011.
330. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP. 2008. A mouse model of Clostridium difficile-associated disease. Gastroenterology 135: 1984-1992. https://doi.org/10.1053/ j.gastro.2008.09.002.
331. Beura LK, Hamilton SE, Bi K, Schenkel JM, Odumade OA, Casey KA, Thompson EA, Fraser KA, Rosato PC, Filali-Mouhim A, Sekaly RP, Jenkins MK, Vezys V, Haining WN, Jameson SC, Masopust D. 2016. Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature 532: 512-516. https://doi.org/10.1038/nature17655.
332. Chiang JY. 2009. Bile acids: regulation of synthesis. J Lipid Res 50: 1955-1966. https://doi.org/10.1194/jlr.R900010-JLR200.
333. Li SS, Zhu A, Benes V, Costea PI, Hercog R, Hildebrand F, Huerta-Cepas J, Nieuwdorp M, Salojärvi J, Voigt AY, Zeller G, Sunagawa S, de Vos WM, Bork P. 2016. Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science 352: 586-589. https://doi.org/10.1126/science.aad8852.
334. Hickson M, D’Souza AL, Muthu N, Rogers TR, Want S, Rajkumar C, Bulpitt CJ. 2007. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 335: 80. https://doi.org/10.1136/ bmj.39231.599815.55.
335. Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. 2010. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 105: 1636-1641. https://doi.org/10.1038/ ajg.2010.11.
336. Thomas MR, Litin SC, Osmon DR, Corr AP, Weaver AL, Lohse CM. 2001. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Mayo Clin Proc 76: 883-889. https://doi.org/10.4065/76.9.883.
337. Plummer S, Weaver MA, Harris JC, Dee P, Huter J. 2004. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 7: 59-62.
338. Lawrence SJ, Korzenik JR, Mundy LM. 2005. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 54: 905-906. https:// doi.org/10.1099/jmm.0.46096-0.
339. Stein G, Nanim R, Karniel E, Moskowitz I, Zeidman A. 2007. Probiotics as prophylactic agents against antibiotic-associated diarrhea in hospitalized patients. Harefuah 146: 520-522, 575.
340. Beausoleil M, Fortier N, Guénette S, L’Ecuyer A, Savoie M, Franco M, Lachaîne J, Weiss K. 2007. Effect of a fermented milk combining Lactobacillus acidophilus CL1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebocontrolled trial. Can J Gastroenterol 21: 732-736. https://doi.org/10.1155/2007/720205.
341. Safdar N, Barigala R, Said A, McKinley L. 2008. Feasibility and tolerability of probiotics for prevention of antibiotic-associated diarrhoea in hospitalized US military veterans. J Clin Pharm Ther 33: 663-668. https:// doi.org/10.1111/j.1365-2710.2008.00980.x.
342. Wullt M, Hagslätt M-LJ, Odenholt I. 2003. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 35: 365-367. https://doi.org/10.1080/00365540310010985.
343. Sampalis J, Psaradellis E, Rampakakis E. 2010. Efficacy of BIO K+ CL1285 in the reduction of antibiotic-associated diarrhea-a placebo controlled double-blind randomized, multi-center study. Arch Med Sci 6: 56-64. https://doi.org/10.5114/aoms.2010.13508.
344. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, Garcia RJ, Brandmarker S, Bowen K, Borjal D, Elmer GW. 2000. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31: 1012-1017. https://doi.org/10.1086/318130.
345. Kotowska M, Albrecht P, Szajewska H. 2005. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 21: 583-590. https://doi.org/10.1111/j.1365-2036.2005.02356.x.
346. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, van Belle G. 1989. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 96: 981-988. https:// doi.org/10.1016/0016-5085(89)91613-2.
347. Surawicz CM, McFarland L, Elmer G, Chinn J. 1989. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol 84: 1285-1287.
348. McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL. 1995. Prevention of B-lactam associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 90: 439-448.
349. Lewis S, Potts L, Barry R. 1998. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect 36: 171-174. https://doi.org/10.1016/ S0163-4453(98)80008-X.
350. Can M, Beşirbellioglu BA, Avci IY, Beker CM, Pahsa A. 2006. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. Med Sci Monit 12: PI19-PI22.
351. Forsyth CB, Farhadi A, Jakate SM, Tang Y, Shaikh M, Keshavarzian A. 2009. Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol 43: 163-172. https://doi.org/10.1016/ j.alcohol.2008.12.009.
352. Orlando A, Linsalata M, Notarnicola M, Tutino V, Russo F. 2014. Lactobacillus GG restoration of the gliadin induced epithelial barrier disruption: the role of cellular polyamines. BMC Microbiol 14: 19. https://doi.org/10.1186/1471-2180-14-19.
353. Seth A, Yan F, Polk DB, Rao RK. 2008. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC-and MAP kinase-dependent mechanism. Am J Physiol Gastrointest Liver Physiol 294: G1060-G1069. https://doi.org/10.1152/ajpgi.00202.2007.
354. Resta-Lenert S, Barrett KE. 2003. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 52: 988-997. https://doi.org/10.1136/gut.52.7.988.
355. Yang KM, Jiang ZY, Zheng CT, Wang L, Yang XF. 2014. Effect of Lactobacillus plantarum on diarrhea and intestinal barrier function of young piglets challenged with enterotoxigenic Escherichia coli K88. J Anim Sci 92: 1496-1503. https://doi.org/10.2527/jas.2013-6619.
356. Von Bültzingslöwen I, Adlerberth I, Wold A, Dahlén G, Jontell M. 2003. Oral and intestinal microflora in 5-fluorouracil treated rats, translocation to cervical and mesenteric lymph nodes and effects of probiotic bacteria. Oral Microbiol Immunol 18: 278-284. https://doi.org/10.1034/ j.1399-302X.2003.00075.x.
357. Ewaschuk JB, Diaz H, Meddings L, Diederichs B, Dmytrash A, Backer J, Looijer-van Langen M, Madsen KL. 2008. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am J Physiol Gastrointest Liver Physiol 295: G1025-G1034. https:// doi.org/10.1152/ajpgi.90227.2008.
358. Ukena SN, Singh A, Dringenberg U, Engelhardt R, Seidler U, Hansen W, Bleich A, Bruder D, Franzke A, Rogler G, Suerbaum S, Buer J, Gunzer F, Westendorf AM. 2007. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One 2: e1308. https:// doi.org/10.1371/journal.pone.0001308.
359. Zareie M, Johnson-Henry K, Jury J, Yang P-C, Ngan B-Y, McKay DM, Soderholm JD, Perdue MH, Sherman PM. 2006. Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut 55: 1553-1560. https:// doi.org/10.1136/gut.2005.080739.
360. Dahan S, Dalmasso G, Imbert V, Peyron J, Rampal P, Czerucka D. 2003. Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun 71: 766-773. https://doi.org/10.1128/IAI.71.2.766-773.2003.
361. Chen X, Kokkotou EG, Mustafa N, Bhaskar KR, Sougioultzis S, O’Brien M, Pothoulakis C, Kelly CP. 2006. Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem 281: 24449-24454. https://doi.org/10.1074/jbc.M605200200.
362. Jahn H-U, Ullrich R, Schneider T, Liehr R-M, Schieferdecker HL, Holst H, Zeitz M. 1996. Immunological and trophical effects of Saccharomyces boulardi on the small intestine in healthy human volunteers. Digestion 57: 95-104.
363. Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Lli MC, Novi M, Rigante D, Cazzato IA, Ojetti V, Armuzzi A, Gasbarrini G, Gasbarrini A. 2006. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 23: 1567-1574. https://doi.org/10.1111/j.1365-2036.2006.02927.x.
364. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O’Neil DA, Macfarlane GT. 2005. Synbiotic therapy (Bifidobacterium longum/ Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 54: 242-249. https://doi.org/10.1136/gut.2004.044834.
365. Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. 1997. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11: 853-858. https://doi.org/10.1046/j.1365-2036.1997.00225.x.
366. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB. 2005. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100: 1539-1546. https://doi.org/10.1111/j.1572-0241.2005.41794.x.
367. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, Forti G, Morini S, Hassan C, Pistoia MA, Modeo ME, Rodino S, D’Amico T, Sebkova L, Sacca N, Di Giulio E, Luzza F, Imeneo M, Larussa T, Di Rosa S, Annese V, Danese S, Gasbarrini A. 2010. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 105: 2218-2227. https://doi.org/10.1038/ajg.2010.218.
368. Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, Tandon RK. 2009. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 7: 1202-1209. https://doi.org/10.1016/j.cgh.2009.07.016.
369. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, Campieri M. 1999. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 13: 1103-1108. https://doi.org/10.1046/j.1365-2036.1999.00560.x.
370. Li G, Zeng S, Liao W, Lv N. 2012. The effect of bifid triple viable on immune function of patients with ulcerative colitis. Gastroenterol Res Pract 2012: 404752. https://doi.org/10.1155/2012/404752.
371. Guslandi M, Giollo P, Testoni PA. 2003. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 15: 697-698. https://doi.org/10.1097/00042737-200306000-00017.
372. Tamaki H, Nakase H, Inoue S, Kawanami C, Itani T, Ohana M, Kusaka T, Uose S, Hisatsune H, Tojo M, Noda T, Arasawa S, Izuta M, Kubo A, Ogawa C, Matsunaka T, Shibatouge M. 2016. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: a randomized, double-blinded, placebocontrolled multicenter trial. Dig Endosc 28: 67-74. https://doi.org/10.1111/den.12553.
373. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. 2004. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 10: PI126-PI131.
374. Ng SC, Plamondon S, Kamm MA, Hart AL, Al-Hassi HO, Guenther T, Stagg AJ, Knight SC. 2010. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm Bowel Dis 16: 1286-1298. https://doi.org/10.1002/ibd.21222.
375. Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, Otsuka M, Hasunuma O, Kurihara R, Iwasaki A, Arakawa Y. 2004. Randomized placebo-controlled trial assessing the effect of bifidobacteriafermented milk on active ulcerative colitis. Aliment Pharmacol Ther 20: 1133-1141. https://doi.org/10.1111/j.1365-2036.2004.02268.x.
376. Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. 2011. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis 5: 115-121. https://doi.org/10.1016/j.crohns.2010.11.004.
377. Peran L, Sierra S, Comalada M, Lara-Villoslada F, Bailón E, Nieto A, Concha A, Olivares M, Zarzuelo A, Xaus J, Gálvez J. 2007. A comparative study of the preventative effects exerted by two probiotics, Lactobacillus reuteri and Lactobacillus fermentum, in the trinitrobenzenesulfonic acid model of rat colitis. Br J Nutr 97: 96-103. https://doi.org/10.1017/S0007114507257770.
378. Chauhan R, Vasanthakumari AS, Panwar H, Mallapa RH, Duary RK, Batish VK, Grover S. 2014. Amelioration of colitis in mouse model by exploring antioxidative potentials of an indigenous probiotic strain of Lactobacillus fermentum Lf1. Biomed Res Int 2014: 206732. https://doi.org/10.1155/2014/206732.
379. Schreiber O, Petersson J, Phillipson M, Perry M, Roos S, Holm L. 2009. Lactobacillus reuteri prevents colitis by reducing P-selectin-associated leukocyte-and platelet-endothelial cell interactions. Am J Physiol Gastrointest Liver Physiol 296: G534-G542. https://doi.org/10.1152/ ajpgi.90470.2008.
380. Zuo L, Yuan K, Yu L, Meng Q, Chung PC, Yang D. 2014. Bifidobacterium infantis attenuates colitis by regulating T cell subset responses. World J Gastroenterol 20: 18316-18329. https://doi.org/10.3748/ wjg.v20.i48.18316.
381. Lee SK, Kim YW, Chi SG, Joo YS, Kim HJ. 2009. The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis. Dig Dis Sci 54: 255-263. https://doi.org/10.1007/s10620-008-0357-0.
382. Dalmasso G, Cottrez F, Imbert V, Lagadec P, Peyron J-F, Rampal P, Czerucka D, Groux H, Foussat A, Brun V. 2006. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 131: 1812-1825. https://doi.org/10.1053/j.gastro.2006.10.001.
383. Dalmasso G, Loubat A, Dahan S, Calle G, Rampal P, Czerucka D. 2006. Saccharomyces boulardii prevents TNF-alpha-induced apoptosis in EHEC-infected T84 cells. Res Microbiol 157: 456-465. https://doi.org/10.1016/j.resmic.2005.11.007.
384. Girard P, Pansart Y, Gillardin JM. 2005. Inducible nitric oxide synthase involvement in the mechanism of action of Saccharomyces boulardii in castor oil-induced diarrhoea in rats. Nitric Oxide 13: 163-169. https:// doi.org/10.1016/j.niox.2005.06.001.
385. Soyturk M, Saygili SM, Baskin H, Sagol O, Yilmaz O, Saygili F, Akpinar H. 2012. Effectiveness of Saccharomyces boulardii in a rat model of colitis. World J Gastroenterol 18: 6452-6460. https://doi.org/10.3748/ wjg.v18.i44.6452.
386. Caetano MJ, Paramés M, Babo M, Santos A, Ferreira AB, Freitas A, Coelho MC, Mateus AM. 1986. Immunopharmacological effects of Saccharomyces boulardii in healthy human volunteers. Int J Immunopharmacol 8: 245-259. https://doi.org/10.1016/0192-0561(86)90106-2.